Tetrabenazine (Nitoman/Xenazine)

Tetrabenazine (Trade name: Nitoman/Xenazine) is a vesicular monoamine transporter 2 (VMAT2) inhibitor used in the treatment of Huntington's Disease and tardive dyskinesia.

Pharmacokinetics of Tetrabenazine

Tetrabenazine: Cytochrome P450 Metabolism

Substrate of (Metabolized by)

Dosing for Tetrabenazine

  • Tetrabenazine comes in

Tetrabenazine should not be taken under the following circumstances:

  • Known hypersensitivity to tetrabenazine
  • In patients with currently untreated or inadequately treated episodes of clinical depression
  • If administered together with a monoamine oxidase inhibitor (MAOI)
    • At least 14 days should elapse between the discontinuation of an MAOI and initiation of treatment with tetrabenazine, and vice versa (between the discontinuation of tetrabenazine and the initiation of treatment with an MAOI)
  • Impaired hepatic function
  • In patients taking reserpine
  • Tetrabenazine can cause depression as it causes a depletion of amines, therefore, untreated depression is a contraindication.